NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ethyreal Bio

Ethyreal Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.ethyrealbio.com/

Last Round

Series B

Jun 10, 2026

Total Funding Raised

$161M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Ethyreal Bio is a biotechnology company developing ETHY-001, a monoclonal antibody antagonist of the thyroid stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodyGraves' diseasethyroid eye diseasemAbTEDGDTSHR blockerthyroid-stimulating hormone receptorTSHRthyroid disease treatmentclinical-stage biotechautoimmune disease therapydrug developmentsubcutaneous injectionprecision therapybiologic drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ethyreal Bio Comps

Public and private peers based on sector, stage, and business model.

Ethyreal Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ethyreal Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 10, 2026
Series BJan 1, 2026
Series AJun 1, 2024

Ethyreal Bio Investors

Notable investors and investment history

Ethyreal Bio investors
InvestorRounds
Avoro CapitalSeries B
Atlas VentureSeries B, Series A
MedicxiSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 10, 2026

    $60M round led by Avoro Capital.

  • Jan 1, 2026

    $60M round led by Avoro Capital

Ethyreal Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ethyreal Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ethyreal Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2024
Last FundingJun 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.